Connect with us

coronavirus

Commission puts forward a revised export transparency and authorization mechanism and measures for accelerated approval of adapted vaccines against COVID-19 variants

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Commission has introduced the principles of reciprocity and proportionality as new criteria to be considered for authorizing exports under the transparency and authorisation mechanism for COVID-19 vaccine exports. This system has significantly improved the transparency of exports. Nevertheless, the objective to ensure timely access to COVID-19 vaccines for EU citizens is still not met. A press release is available online.

Also, as an immediate action under the HERA Incubator, the new European bio-defence preparedness plan against COVID-19 variants, the Commission is introducing a measure to speed up the authorisation of adapted COVID-19 vaccines. It will make provisions in the relevant EU legislation to allow companies to focus on gathering the necessary evidence in time and enable the authorisation of adapted vaccines with a smaller set of additional data submitted to the European Medicines Agency. A press release is available here.

You can follow the press conference by Executive Vice-President Valdis Dombrovskis and Commissioner Stella Kyriakides on EbS.

Share this article:

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter.

Trending